ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Pulse Biosciences Inc

Pulse Biosciences Inc (PLSE)

11.37
-0.58
(-4.85%)
Closed May 27 4:00PM
11.40
0.03
(0.26%)
After Hours: 7:59PM

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
11.37
Bid
7.50
Ask
13.25
Volume
208,655
10.74 Day's Range 12.00
3.78 52 Week Range 13.62
Market Cap
Previous Close
11.95
Open
11.71
Last Trade
20
@
11.37
Last Trade Time
Financial Volume
$ 2,356,299
VWAP
11.2928
Average Volume (3m)
185,947
Shares Outstanding
54,991,487
Dividend Yield
-
PE Ratio
-14.85
Earnings Per Share (EPS)
-0.77
Revenue
-
Net Profit
-42.21M

About Pulse Biosciences Inc

Pulse Biosciences Inc is a medical therapy company that pursues the commercial introduction of its proprietary CellFX System utilizing its patent-protected Nano-Pulse Stimulation (NPS) platform technology. Through its proprietary CellFX System, the company can deliver a cell-focused effect on dysfun... Pulse Biosciences Inc is a medical therapy company that pursues the commercial introduction of its proprietary CellFX System utilizing its patent-protected Nano-Pulse Stimulation (NPS) platform technology. Through its proprietary CellFX System, the company can deliver a cell-focused effect on dysfunctional cells while preserving surrounding non-cellular tissue, a combination that may potentially lead to both improved efficacy and less collateral tissue damage. Substantial revenue is generated from North America Majorly due to the sale of systems. Show more

Sector
Surgical,med Instr,apparatus
Industry
Surgical,med Instr,apparatus
Headquarters
Wilmington, Delaware, USA
Founded
1970
Pulse Biosciences Inc is listed in the Surgical,med Instr,apparatus sector of the NASDAQ with ticker PLSE. The last closing price for Pulse Biosciences was $11.95. Over the last year, Pulse Biosciences shares have traded in a share price range of $ 3.78 to $ 13.62.

Pulse Biosciences currently has 54,991,487 shares outstanding. The market capitalization of Pulse Biosciences is $626.90 million. Pulse Biosciences has a price to earnings ratio (PE ratio) of -14.85.

PLSE Latest News

Pulse Biosciences Announces Updated Timing of Rights Offering for Up to $60,000,000

Pulse Biosciences, Inc. (Nasdaq: PLSE) (“Pulse” or the “Company”), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced...

Pulse Biosciences’ CellFX Nanosecond Pulsed Field Ablation (nsPFA™) Technology to be Featured in Several Presentations at The Heart Rhythm Society 2024 Annual Meeting

Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced CellFX nsPFA technology will...

Pulse Biosciences Enhances Executive Leadership Team

Appoints proven atrial fibrillation medical technology leader Burke T. Barrett as President and Chief Executive Officer Former President and Chief Executive Officer Kevin Danahy appointed as...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
13.4543.56060606067.9212.197.632332610.89574432CS
44.6669.44858420276.7112.196.652129848.75381351CS
121.312.90963257210.0712.196.5951859478.58545945CS
264.770.46476761626.6713.626.5952377979.39671499CS
525.2686.08837970546.1113.623.782032737.94579283CS
156-7.27-39.002145922718.6429.161.181570517.13309088CS
260-0.47-3.9695945945911.8445.821.181301209.70869832CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
LUCYInnovative Eyewear Inc
$ 0.983
(428.49%)
944.4M
AKANAkanda Corporation
$ 4.07
(70.29%)
39.11M
TKLFYoshitsu Company Ltd
$ 0.3496
(53.33%)
84.5M
ONMDOneMedNet Corporation
$ 2.251
(53.13%)
136.04M
MRUSMerus NV
$ 59.92
(35.97%)
6.91M
VSTMVerastem Inc
$ 4.0901
(-66.42%)
19.68M
TOIIWOncology Institute Inc
$ 0.0443
(-55.61%)
280.55k
SNSESensei Biotherapeutics Inc
$ 0.7912
(-45.43%)
1.41M
GNLXGenelux Corporation
$ 2.61
(-43.26%)
3.32M
AUVIApplied UV Inc
$ 0.32
(-33.33%)
5.18M
LUCYInnovative Eyewear Inc
$ 0.983
(428.49%)
944.4M
GWAVGreenwave Technology Solutions Inc
$ 0.0843
(-4.85%)
428.98M
NCPLNetcapital Inc
$ 0.20
(14.42%)
191.35M
HLTHCue Health Inc
$ 0.0931
(-1.27%)
160.21M
ONMDOneMedNet Corporation
$ 2.251
(53.13%)
136.04M

PLSE Discussion

View Posts
Monksdream Monksdream 2 months ago
PLSE 10Q due March 14
👍️0
Monksdream Monksdream 3 months ago
PLSE 10Q due March 7
👍️0
NRS NRS 1 year ago
Taking off after Thursday's earnings phone call!
👍️0
NRS NRS 1 year ago
#PLSE Recent insider transactions: https://simplywall.st/stocks/us/healthcare/nasdaq-plse/pulse-biosciences/ownership?blueprint=2299718
👍️0
NRS NRS 1 year ago
$PLSE article: Insiders own %57 of o/s (55% owned by Robert Duggan, 2% by other insiders). Institutions own 6.7%.
https://finance.yahoo.com/news/pulse-biosciences-inc-nasdaq-plse-122414850.html?.tsrc=rss
👍️0
NRS NRS 1 year ago
85% chance predicted yesterday for a move higher:
https://tickeron.com/ticker/PLSE/
$PLSE
👍️0
NRS NRS 1 year ago
Tickeron on Twitter (17.8k followers) posts:
$PLSE's Aroon indicator reaches into Uptrend on January 11, 2023. View odds for this and other indicators: https://t.co/rb3VuLqkuK #PulseBiosciences #stockmarket #stock pic.twitter.com/i1VoiqtqoA— Tickeron (@Tickeron) January 12, 2023
$PLSE
👍️0
NRS NRS 1 year ago
SYD on Twitter posts potential to fill to $4.70's. $PLSE: $PLSE nice vcp contraction then breakout. above sma200. potential gap fill around 4.70s pic.twitter.com/MGacthBt1P— 許文龍 (@chft_500) January 10, 2023
👍️0
NRS NRS 1 year ago
Nice moves last couple days.
👍️0
subslover subslover 2 years ago
Pulse Biosciences Announces FDA 510(k) Clearance for the Treatment of Sebaceous Hyperplasia
September 26 2022 - 08:00AM
Business Wire
Alert
Print
Share On Facebook
Additional 510(k) clearance recently received for use of larger spot size treatment tips with the CellFX System

Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company developing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, today announced receipt of U.S. Food and Drug Administration (FDA) 510(k) clearance for its CellFX System, expanding the indication for use to include the treatment of sebaceous hyperplasia in patients with Fitzpatrick skin types I-III. This specific indication clearance enhances the CellFX System’s general indication FDA clearance and enables the Company to support clinics in marketing and promoting CellFX treatments specifically for patients with sebaceous hyperplasia. The clearance was based on clinical data from the Company’s IDE approved study for the treatment of sebaceous hyperplasia.

The Company also recently received FDA 510(k) clearance of two additional treatment tips with larger spot sizes, specifically 7.5mm and 10mm tip sizes, for treating larger benign lesions. These treatment tips broaden the portfolio of previously available 1.5mm, 2.5mm and 5.0mm treatment tip sizes.

“We are pleased with the continued advancement of the CellFX System and its capabilities to enhance its value proposition for patients, clinicians and any potential commercial partner. These clearances provide further validation of the system’s strong safety and effectiveness profile,” said Kevin Danahy, President and Chief Executive Officer of Pulse Biosciences. “We would like to thank all of the investigators, the staff at their clinics and the patients who participated in these trials, as well as the FDA for their ongoing collaboration as we endeavor to offer the benefits of NPS technology to more patients.”

About Pulse Biosciences®

Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the potential to improve the quality of life for patients. The Company’s proprietary Nano-Pulse Stimulation technology delivers nano-second pulses of electrical energy to non-thermally clear cells while sparing adjacent non-cellular tissue. The CellFX® System is the first commercial product to harness the distinctive advantages of NPS technology to treat a variety of conditions for which an optimal solution remains unfulfilled. The Company is actively pursuing application development in cardiology, oncology, gastroenterology, and other medical specialties. Designed as a multi-application platform, the CellFX System offers customer value with a utilization-based revenue model. Visit www.pulsebiosciences.com to learn more.

Pulse Biosciences, CellFX, Nano-Pulse Stimulation, NPS, and the stylized logos are among the trademarks and/or registered trademarks of Pulse Biosciences, Inc. in the United States and other countries.

Forward-Looking Statements

All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to Pulse
👍️0
ClarkKant ClarkKant 7 years ago
$VERI -$4.70 3rd leg down @ $23.80 in @ $23.85 tight SL
👍️0
crudeoil24 crudeoil24 7 years ago
INOV up 20% > https://ih.advfn.com/p.php?pid=nmona&article=75627253
👍️0
TheFinalCD TheFinalCD 7 years ago
SWEET ALERT= https://investorshub.advfn.com/boards/read_msg.aspx?message_id=134517877


CONGRAT$


👍️0
ClarkKant ClarkKant 7 years ago
Someone dumped 100k shares down to @ $11s caused the short circuit. Sub $10 is a good bet maybe although it was starting to bounce of the $11's to the $12.50 before the short circuit kicked in.
👍️0
Philmasta Philmasta 7 years ago
I am hoping that means FDA approval is close.
👍️0
sokol sokol 7 years ago
Insider buying.

Pulse Biosciences, Inc (NASDAQ:PLSE) Director Maky Zanganeh acquired 28,790 shares of the business's stock in a transaction dated Thursday, August 3rd. The shares were bought at an average price of $23.96 per share, for a total transaction of $689,808.40. Following the completion of the acquisition, the director now owns 287,225 shares in the company, valued at $6,881,911. The acquisition was disclosed in a legal filing with the SEC.

Director Maky Zanganeh bought 8,290 shares of Pulse Biosciences stock in a transaction dated Wednesday, August 2nd.

Pulse Biosciences, Inc (NASDAQ:PLSE) major shareholder Robert W. Duggan acquired 277,450 shares of Pulse Biosciences stock in a transaction on Thursday, August 3rd. The stock was acquired at an average price of $23.14 per share, with a total value of $6,420,193.00. Following the purchase, the insider now directly owns 3,153,234 shares in the company, valued at $72,965,834.76. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Major shareholders that own at least 10% of a company's stock are required to disclose their transactions with the SEC.
👍️0
sokol sokol 7 years ago
Insider buying.

Pulse Biosciences, Inc (NASDAQ:PLSE) Director Maky Zanganeh acquired 28,790 shares of the business's stock in a transaction dated Thursday, August 3rd. The shares were bought at an average price of $23.96 per share, for a total transaction of $689,808.40. Following the completion of the acquisition, the director now owns 287,225 shares in the company, valued at $6,881,911. The acquisition was disclosed in a legal filing with the SEC.

Director Maky Zanganeh bought 8,290 shares of Pulse Biosciences stock in a transaction dated Wednesday, August 2nd.

Pulse Biosciences, Inc (NASDAQ:PLSE) major shareholder Robert W. Duggan acquired 277,450 shares of Pulse Biosciences stock in a transaction on Thursday, August 3rd. The stock was acquired at an average price of $23.14 per share, with a total value of $6,420,193.00. Following the purchase, the insider now directly owns 3,153,234 shares in the company, valued at $72,965,834.76. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Major shareholders that own at least 10% of a company's stock are required to disclose their transactions with the SEC.
👍️0
Converter Converter 7 years ago
What's happening with this stick now?? Sheesh!
👍️0
MillionaireBy28 MillionaireBy28 7 years ago
Looking great here
👍️0
3DYOGI 3DYOGI 7 years ago
It's coming boom time for Bio Electronic sector



$ENDV
$PLSE
👍️0
whizknock whizknock 7 years ago
3DYOGI,,, You're absolutely right! PLSE has a market cap 23.5 times that of ENDV & will at some point probably need to pay license fees for ENDV patents.

Yes, ENDV is further along & if it had a market cap of 330 million like PLSE it would be trading @ $1.50

Not bad when you consider ENDV is currently trading @ .065
👍️0
3DYOGI 3DYOGI 7 years ago
ENDV further along than Pulse CEO has spent half his sparky buying open shares at an average price of .26 he now owns over 20 million shares insiders own over 40 million on 85 million floating

PLSE 360 million market cap
ENDV 14 million market cap
👍️0
edge edge 7 years ago
Loving this stock from 17.34 17.35, sold 90% @ 20.50 pre market last week and I'm an idiot..........
👍️0
7K21M 7K21M 7 years ago
Bullish. In at 19.20
👍️0
stocktrademan stocktrademan 7 years ago
PLSE bullish 19.94









normal chart




log chart



👍️0

Your Recent History

Delayed Upgrade Clock